Inhibitor Therapeutics (INTI) Income from Non-Controlling Interests (2013)
Inhibitor Therapeutics' (INTI) quarterly Income from Non-Controlling Interests came in at $1889.0 in Q4 2013.
Inhibitor Therapeutics (INTI) Income from Non-Controlling Interests (2013) Analysis & Trends
Inhibitor Therapeutics (INTI) has 1 years of Income from Non-Controlling Interests data on file, last reported at $1889.0 in Q4 2013.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $1889.0 in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $1889.0 (changed N/A YoY) and the FY2023 annual result came in at $17000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests was little changed at $1889.0 in Q4 2013.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $1889.0 in Q4 2013 to a low of $1889.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 1,889.00 |